Jinyu Bio-Technology Co., Ltd. Class A

Jinyu Bio-Technology Co., Ltd. Class A

SSSE:600201
11.90
CNY
-0.10
(-0.83%)
0.16EPS
78.27P/E
12.77BMarket Cap
Apr 16Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.65
1.04
1.21
1.45
1.68
1.68
1.02
1.4
1.58
1.38
1.47
1.15
1.26
1.44
Basic EPS, GAAP
0.24
0.4
0.47
0.62
0.77
0.67
0.2
0.36
0.34
0.19
0.26
0.1
0.09
0.15
Free Cash Flow per Basic Share
0.52
0.37
0.23
0.59
0.48
-0.11
0.09
0.42
0.14
0.14
0.13
0.18
0.18
- -
Dividend per Share
0.06
0.08
0.08
0.22
0.27
0.24
0.37
0.06
0.12
0.11
0.06
0.08
0.03
- -
Book Value per Share
1.25
1.57
1.98
3.36
3.82
4.28
4.13
4.42
4.68
4.53
4.79
4.74
4.83
4.79
Tangible Book Value per Share
1.2
1.51
1.89
3.12
3.52
3.74
3.55
3.79
4.02
3.9
4.13
4.15
4.2
4.07
Basic Weighted Avg Shares
1,026
1,022
1,027
1,047
1,130
1,126
1,105
1,128
1,124
1,109
1,091
1,090
1,112
1,111
Sales/Revenue/Turnover
671
1,063
1,247
1,517
1,901
1,897
1,127
1,582
1,776
1,529
1,598
1,255
1,396
1,604
Operating Margin (%)
35.94
45.45
47.36
49.76
51.74
45.51
24.27
27.81
24
19.47
20.32
11.44
8.58
20.12
Depreciation Expense
41
47
71
59
62
97
107
174
192
200
189
217
259
- -
Net Income, GAAP
251
404
480
645
870
754
221
406
382
211
284
109
100
165
Effective Tax Rate (%)
16.91
16.74
19.51
17.55
15.33
15.71
10.5
11.3
5.87
18.51
12.26
16.62
8.71
15.64
Profit Margin (%)
37.37
38.04
38.49
42.49
45.77
39.78
19.62
25.68
21.52
13.78
17.75
8.68
7.17
10.27
Working Capital
777
935
1,108
2,718
3,058
2,739
2,146
2,507
2,071
2,022
2,175
1,466
1,623
2,220
LT Debt
10
- -
- -
- -
3
3
15
- -
- -
- -
3
1
- -
270
Total Equity
1,282
1,630
2,069
3,753
4,478
5,196
4,869
5,263
5,560
5,350
5,655
5,415
5,551
5,388
Return on Invested Capital (%)
17.67
26.41
25.45
21.62
20.86
15.34
4.5
8.41
7.27
3.84
5.07
1.9
1.78
3.16
Return on Capital (%)
19.21
26.78
26.05
22.2
21.18
15.74
4.42
7.69
6.94
4.12
5.27
2.13
1.91
2.77
Return on Common Equity (%)
21.28
27.75
25.92
22.16
21.17
15.92
4.58
8.44
7.46
4.07
5.43
2.04
1.87
3.1

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1
1
1
LT Borrowings
- -
100
270
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,112
1,112
1,100
Market Capitalization
16,009
12,952
12,770

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,375
2,824
2,866
Cash, Cash Equivalents & STI
1,320
1,670
1,702
Accounts Receivable, Net
696
801
824
Inventories
260
264
236
Total Current Liabilities
648
670
646
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.44%
1.17%
2.5%
Free Cash Flow
19.51%
-7.89%
-2.6%
Net Income, GAAP
-1.67%
-17.17%
-8.14%
Sales/Revenue/Turnover
3.93%
-1.46%
11.23%
Total Cash Common Dividend
17.39%
2.91%
-62.72%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
348
264
359
285
1,255
2025
352
268
- -
354
1,396
2026
346
410
493
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.1
0.02
0.04
-0.06
0.1
2025
0.07
-0.01
- -
-0.06
0.09
2026
0.07
0.02
0.11
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.08
2025
- -
0.03
- -
- -
0.03
2026
- -
- -
- -
- -
- -

Company Description

CEO
Jing Zhang
Full Time Employees
1,881
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Shaerqin Industrial Park Hohhot MO China 010111
IPO Date
Jan 15, 1999
Business
Jinyu Bio-Technology Co., Ltd. (600201.SS) engages primarily in the research, development, production, and sale of veterinary biological products in China. The company offers a comprehensive portfolio of over 110 animal vaccines and diagnostic products covering swine, ruminant, avian, and companion animals; key offerings include foot-and-mouth disease (FMD) vaccines, where it ranks as China's top producer and supplier with 10 billion mL produced in the past decade, porcine vaccines such as those for mycoplasma pneumoniae, porcine reproductive and respiratory syndrome, and pseudorabies, ruminant vaccines for brucellosis, bovine viral diarrhea, and mucosal disease, avian vaccines, pet vaccines including rabies, and diagnostic reagents. It operates through five subsidiaries focused on the animal health industry, supported by three Chinese national laboratories and advanced manufacturing at the Jinyu Bio-Technology Industrial Park in Inner Mongolia, which features seven intelligent vaccine production lines and two diagnostic reagent lines introduced in 2019. Founded in 1993 and listed on the Shanghai Stock Exchange in 1999, Jinyu Bio-Technology is headquartered at No. 1 Jinyu Street, Shaerqin Industrial Park, Hohhot, Inner Mongolia, China, with approximately 1,740 employees; it also conducts ancillary activities in textile processing, property leasing and management, and energy products. Recent developments include a recovery in core product sales and overall operations as of the first three quarters of 2025, with revenue reaching RMB 1.042 billion, up 7.38% year-over-year, alongside obtaining a new veterinary drug registration certificate for a gene-engineered subunit vaccine against Clostridium perfringens (Type A) in cattle and cumulative share repurchases representing 1.4134% of outstanding shares.